Demand has broadened across independent fronts: growth is now coming from several distinct, currently-producing sources
The model's full reasoning — Q4 2022 call → NOWe need to determine if management describes current growth being carried by at least three distinct, independent sources at the same time, each already producing real current business, and that this breadth is recent/building. The transcript mentions: U.S. and international segments, uveitis indication launches in new countries, DME growth, NEW DAY study (but that's clinical, not current revenue), Ocumension license (one-time revenue in 2021, not current), distributor purchase orders for 2023, etc. But are there three distinct engines? They mention U.S. product revenue, international product revenue, and within international, uveitis launches in new markets. Also they mention DME and uveitis as two indications. But are these genuinely different in kind? U.S. and international are geographies. Uveitis vs DME are different indications but same product. Also they mention the DRCR Protocol AL trial (not current revenue). The question asks for at least three genuinely different engines such as different products, customer types, end markets, geographies, channels, or ways of earning. They have U.S. and international geographies, and within international, new uveitis launches. But is that three? U.S. DME, international DME, international uveitis? They also mention distributor orders. But management does not explicitly frame it as three distinct engines. They talk about growth driven by U.S. and international segments, and within international, uveitis launches. But they don't say "we have three engines." Also they mention that global end user demand growth was 23% U.S. and 21% international. That's two geographies. Uveitis is an indication, not a separate product. The question requires at least three distinct sources. Also they mention the Ocumension license as one-time, not current. They also mention the NEW DAY study as future. So likely answer is NO because they only have two main engines: U.S. and international. Even if uveitis is a new indication, it's part of international. Also they mention that the growth is recent? They say "returned to pre-pandemic levels" and "we are excited to see the impact of ILUVIEN being available for physicians and patients in these newly launched markets for a full year in 2023." That suggests uveitis is a newer front, but it's still within international. So not three distinct.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| E | Eni S.p.A. | Q1 2024 | 2024-04-24 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PSFE | Paysafe Limited | Q4 2023 | 2024-03-07 | C+ |
| FRPH | FRP Holdings, Inc. | Q4 2023 | 2024-03-07 | C+ |
| GTLB | GitLab Inc. | Q4 2024 | 2024-03-04 | C+ |
| INTR | Inter & Co, Inc. | Q4 2023 | 2024-02-08 | B+ |
| TBLA | Taboola.com Ltd. | Q3 2023 | 2023-11-08 | B+ |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ANGO | AngioDynamics, Inc. | Q1 2024 | 2023-10-04 | B |
| CTLP | Cantaloupe, Inc. | Q4 2023 | 2023-09-06 | B+ |
| KMDA | Kamada Ltd. | Q2 2023 | 2023-08-16 | B+ |
| ZOM | Zomedica Corp. | Q2 2023 | 2023-08-10 | C |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| INTT | inTEST Corporation | Q2 2023 | 2023-08-04 | A |
| FOUR | Shift4 Payments, Inc. | Q2 2023 | 2023-08-03 | B+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| PERI | Perion Network Ltd. | Q2 2023 | 2023-08-02 | A |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| EDU | New Oriental Education & Technology Grou | Q3 2023 | 2023-04-19 | B |
| ISRG | Intuitive Surgical, Inc. | Q4 2022 | 2023-01-24 | C |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| UGRO | urban-gro, Inc. | Q1 2022 | 2022-05-13 | D |
| XMTR | Xometry, Inc. | Q1 2022 | 2022-05-11 | B+ |
| CLAR | Clarus Corporation | Q1 2022 | 2022-05-09 | B |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| ABNB | Airbnb, Inc. | Q1 2022 | 2022-05-03 | B+ |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| WSC | WillScot Mobile Mini Holdings Corp. | Q4 2021 | 2022-02-25 | B+ |
| LMND | Lemonade, Inc. | Q4 2021 | 2022-02-24 | D |
| SNOW | Snowflake Inc. | Q3 2022 | 2021-12-01 | A |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| BRAG | Bragg Gaming Group Inc. | Q3 2021 | 2021-11-08 | B+ |
| ENV | Envestnet, Inc. | Q3 2021 | 2021-11-08 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| CROX | Crocs, Inc. | Q3 2021 | 2021-10-21 | B+ |
| DG | Dollar General Corporation | Q2 2021 | 2021-08-26 | A |
| ZIM | ZIM Integrated Shipping Services Ltd. | Q2 2021 | 2021-08-18 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| Z | Zillow Group, Inc. | Q2 2021 | 2021-08-05 | B |
| NOV | NOV Inc. | Q2 2021 | 2021-07-28 | C+ |
| STRA | Strategic Education, Inc. | Q2 2021 | 2021-07-28 | C |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| BCO | The Brink's Company | Q3 2018 | 2018-10-24 | C |
| NDLS | Noodles & Company | Q3 2018 | 2018-10-23 | B+ |
| AUDC | AudioCodes Ltd. | Q3 2018 | 2018-10-23 | A |
| YEXT | Yext, Inc. | Q2 2019 | 2018-08-30 | C+ |
| TNC | Tennant Company | Q2 2018 | 2018-07-25 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| ST | Sensata Technologies Holding plc | Q2 2017 | 2017-07-25 | B+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| HUBB | Hubbell Incorporated | Q2 2017 | 2017-07-25 | B+ |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| PPSI | Pioneer Power Solutions, Inc. | Q4 2016 | 2017-03-10 | B |
| ABR | Arbor Realty Trust, Inc. | Q4 2016 | 2017-03-03 | B+ |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| LGND | Ligand Pharmaceuticals Incorporated | Q4 2016 | 2017-02-23 | C+ |
| PYPL | PayPal Holdings, Inc. | Q4 2016 | 2017-01-26 | B+ |
| PNFP | Pinnacle Financial Partners, Inc. | Q2 2016 | 2016-07-20 | B |
| BX | Blackstone Inc. | Q1 2016 | 2016-04-21 | B |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
GDRX · Q2 2022 → YESThe question is about whether management describes the company's CURRENT growth as being carried by SEVERAL DISTINCT, INDEPENDENT SOURCES AT THE SAME TIME — at least three genuinely different engines,...YES The transcript shows management describing current growth as carried by multiple distinct engines: prescription transactions (still the core but with recent challenges), subscriptions revenue (82% YoY growth), and Pharma Manufacturer Solutions (more than doubled YoY). They explicitly frame the diversification as a recent development, noting that other offerings now make up 30% of revenue compared to 5% just three years ago, with several sources like subscriptions and pharma still having most of their contribution ahead due to significant TAM and low penetration. This breadth is presented as newly meaningful for the company, reflecting the early stage of these newer fronts rather than a long-standing diversified business.
TOUR · Q4 2017 → YESThe question is about whether management describes current growth being carried by several distinct, independent sources at the same time — at least three genuinely different engines — each already pr...YES Management describes current growth as carried by multiple distinct, independent engines that are already producing real revenue and activity: packaged tours (organized and self-guided), financial services and commissions, offline retail stores (18% of GMV in Q4 2017, launched 2016), direct procurement (40% of GM 2017), and corporate TMC services (more than 200% YoY growth). They explicitly note diversification of sales channels (online, mobile, loyalty, offline, B2B/corporate) and that the company was narrower until recently, with offline retail and corporate TMC expanding in 2016–2017 while local operators remain small but growing.
CYBR · Q3 2021 → YESThe question is about whether management describes current growth being carried by several distinct, independent sources at the same time — at least three genuinely different engines — each producing ...YES The transcript shows management describing current growth as driven by multiple distinct, independent engines operating simultaneously: record SaaS bookings and subscription ARR growth (131%), the Identity Security platform centered on Privileged Access Management (PAM) and Privilege Cloud with new logos over 230, EPM with another record quarter, Access and DevSecOps offerings, plus expansion across geographies (every region growing) and verticals (new logos in law firms, software, oil & gas, retailers, government). These are presented as real, current business with concrete metrics and customer examples, not plans.